Esketamine (Spravato) FDA approved for Treatment Resistant Depression.
Esketamine is a glutamate receptor modulator: acts as noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist. On March 05, 2019: FDA approved Spravato (esketamine) nasal spray, as an…
